Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Inclusion Criteria:

* No prior sorafenib
* Histologically or cytologically confirmed uterine carcinoma or carcinosarcoma:

  * Advanced or recurrent disease
  * Not amenable to curative surgery or radiotherapy
* Measurable disease:

  * At least 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan
* Tumor tissue block must be available
* No known brain metastases
* Performance status:

  * ECOG 0-2 OR
  * Karnofsky 60-100%
* Hematopoietic:

  * Absolute neutrophil count \>= 1,500/mm3
  * Platelet count \>= 100,000/mm3
  * No bleeding diathesis
* Hepatic:

  * Bilirubin normal
  * AST and ALT =\< 2.5 times upper limit of normal
* Renal:

  * Creatinine =\< 1.5 mg/dL OR
  * Creatinine clearance \>= 60 mL/min
* Cardiovascular:

  * No uncontrolled hypertension, defined by 1 of the following:

    * Blood pressure \> 150/100 mm Hg
    * Currently taking \> 1 antihypertensive agent
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No other active malignancy
* No history of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib
* No ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* No swallowing dysfunction that would preclude study drug ingestion
* No other uncontrolled illness
* Prior biological response modifier therapy allowed
* No prior antiangiogenesis therapy
* No prior MAPK-signaling agents
* No prior vascular endothelial growth factor receptor (VEGFR) inhibitors
* No more than 1 prior chemotherapy regimen
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
* Prior hormonal therapy allowed
* Prior radiotherapy allowed provided the only site of measurable disease was not located within the radiation port OR disease has progressed since completion of therapy
* Recovered from all prior therapy
* Concurrent warfarin allowed provided all of the following are true:

  * Patient is therapeutic on a stable warfarin dose
  * INR target range =\< 3
  * Patient is monitored with weekly INR testing
  * No active bleeding or pathological condition that carries a high bleeding risk
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)
* No concurrent rifampin
* No concurrent Hypericum perforatum (St. John's wort)
* No other concurrent investigational agents
* No other concurrent anticancer therapy
* More than 4 weeks since prior radiotherapy